mutLBSgeneDB |
Gene summary for PDE2A |
![]() |
Basic gene Info. | Gene symbol | PDE2A |
Gene name | phosphodiesterase 2A, cGMP-stimulated | |
Synonyms | CGS-PDE|PDE2A1|PED2A4|cGSPDE | |
Cytomap | UCSC genome browser: 11q13.4 | |
Type of gene | protein-coding | |
RefGenes | NM_001143839.3, NM_001146209.2,NM_001243784.1,NM_002599.4, | |
Description | cGMP-dependent 3',5'-cyclic phosphodiesterasecGMP-stimulated phosphodiesterase 1cGMP-stimulated phosphodiesterase 4cyclic GMP-stimulated phosphodiesterase | |
Modification date | 20141207 | |
dbXrefs | MIM : 602658 | |
HGNC : HGNC | ||
Ensembl : ENSG00000186642 | ||
HPRD : 04041 | ||
Vega : OTTHUMG00000102045 | ||
Protein | UniProt: O00408 go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_PDE2A | |
BioGPS: 5138 | ||
Pathway | NCI Pathway Interaction Database: PDE2A | |
KEGG: PDE2A | ||
REACTOME: PDE2A | ||
Pathway Commons: PDE2A | ||
Context | iHOP: PDE2A | |
ligand binding site mutation search in PubMed: PDE2A | ||
UCL Cancer Institute: PDE2A | ||
Assigned class in mutLBSgeneDB | A: This gene has a literature evidence and it belongs to targetable_mutLBSgenes. | |
References showing study about ligand binding site mutation for PDE2A. | 1. Heikaus, C. C., Stout, J. R., Sekharan, M. R., Eakin, C. M., Rajagopal, P., Brzovic, P. S., ... & Klevit, R. E. (2008). Solution Structure of the cGMP Binding GAF Domain from Phosphodiesterase 5 INSIGHTS INTO NUCLEOTIDE SPECIFICITY, DIMERIZATION, AND cGMP-DEPENDENT CONFORMATIONAL CHANGE. Journal of Biological Chemistry, 283(33), 22749-22759. 18534985 |
![]() |
GO ID | GO Term | PubMed ID | GO:0000122 | negative regulation of transcription from RNA polymerase II promoter | 17329248 | GO:0006198 | cAMP catabolic process | 14687666 | GO:0008152 | metabolic process | 17329248 | GO:0033159 | negative regulation of protein import into nucleus, translocation | 17329248 | GO:0036006 | cellular response to macrophage colony-stimulating factor stimulus | 14687666 | GO:0046069 | cGMP catabolic process | 14687666 | GO:0071321 | cellular response to cGMP | 17704206 | GO:0097011 | cellular response to granulocyte macrophage colony-stimulating factor stimulus | 14687666 |
Top |
Ligand binding site mutations for PDE2A |
![]() We represented ligand binding site mutations only. (You can see big image via clicking.) ![]() |
![]() |
![]() |
LBS | AAchange of nsSNV | Cancer type | # samples | I866 | A867V | COAD | 1 | I822 | K821R | KIRC | 1 | N704 | T703R | LUAD | 1 | N704 | N704S | LUAD | 1 | L774 | I776M | LUSC | 1 | Y655 | P653T | LUSC | 1 | I866 | A867V | OV | 1 | M847,M845 | E846K | SKCM | 1 | N704 | N704Y | STAD | 1 | N704,H700 | G702C | UCEC | 1 |
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
Top |
Protein structure related information for PDE2A |
![]() Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
![]() ![]() |
![]() |
![]() Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
LBS | AAchange of nsSNV | Relative stability change | N704 | N704Y | 0.21625259 | N704 | N704S | 0.008137558 | L774 | I776M | -1.5330969 | M845 | E846K | -1.2817133 | M847 | E846K | -1.2817133 | I866 | A867V | -1.1876784 | N704 | T703R | -1.0810062 | Y655 | P653T | -1.0619263 | N704 | G702C | -0.48538548 | H700 | G702C | -0.48538548 | I822 | K821R | -0.38224486 |
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
![]() |
Top |
Differential gene expression and gene-gene network for PDE2A |
![]() |
![]() |
Top |
Top |
Phenotype information for PDE2A |
![]() |
Disease ID | Disease name | # PubMed | Association type |
umls:C1458155 | Breast Neoplasms | 1 | Biomarker |
![]() |
Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
Top |
Pharmacological information for PDE2A |
![]() Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
![]() |
![]() |
![]() |
![]() |
Drug status | DrugBank ID | Name | Type | Drug structure |
Experimental | DB02315 | Cyclic Guanosine Monophosphate | Small molecule | ![]() |
Investigational | DB05142 | ND7001 | Small molecule | ![]() |
Experimental | DB07954 | 3-isobutyl-1-methyl-7H-xanthine | Small molecule | ![]() |
Approved | DB08811 | Tofisopam | Small molecule | ![]() |
![]() |
![]() |
![]() |
Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | MG | MAGNESIUM(2+) | 4d09 | C | H700 | MG | MAGNESIUM(2+) | 4d09 | D | H700 | EH9 | (2S,3R)-EHNA | 4c1i | D | I866 | 788 | N-BENZYL-4-METHYL-1-PHENYL[1,2,4]TRIAZOLO[4, 3-A]QUINOXALINE-8-CARBOXAMIDE | 4d09 | D | L774 I822 M847 | 788 | N-BENZYL-4-METHYL-1-PHENYL[1,2,4]TRIAZOLO[4, 3-A]QUINOXALINE-8-CARBOXAMIDE | 4d09 | A | L774 M847 | Q2T | 1-(5-BUTOXYPYRIDIN-3-YL)-4-METHYL-8- (MORPHOLIN-4-YLMETHYL)[1,2,4]TRIAZOLO[4,3-A] QUINOXALINE | 4d08 | C | M845 M847 | 788 | N-BENZYL-4-METHYL-1-PHENYL[1,2,4]TRIAZOLO[4, 3-A]QUINOXALINE-8-CARBOXAMIDE | 4d09 | B | M847 | Q2T | 1-(5-BUTOXYPYRIDIN-3-YL)-4-METHYL-8- (MORPHOLIN-4-YLMETHYL)[1,2,4]TRIAZOLO[4,3-A] QUINOXALINE | 4d08 | D | N704 M845 M847 | Q2T | 1-(5-BUTOXYPYRIDIN-3-YL)-4-METHYL-8- (MORPHOLIN-4-YLMETHYL)[1,2,4]TRIAZOLO[4,3-A] QUINOXALINE | 4d08 | A | N704 M847 | Q2T | 1-(5-BUTOXYPYRIDIN-3-YL)-4-METHYL-8- (MORPHOLIN-4-YLMETHYL)[1,2,4]TRIAZOLO[4,3-A] QUINOXALINE | 4d08 | B | N704 M847 | IBM | 3-ISOBUTYL-1-METHYL-9H-XANTHINE | 3itu | B | Y655 | IBM | 3-ISOBUTYL-1-METHYL-9H-XANTHINE | 3itu | C | Y655 | IBM | 3-ISOBUTYL-1-METHYL-9H-XANTHINE | 3itu | D | Y655 | EH9 | (2S,3R)-EHNA | 4c1i | A | Y655 | EH9 | (2S,3R)-EHNA | 4c1i | C | Y655 | 1L6 | 1-(2-HYDROXYETHYL)-3-(2-METHYLBUTAN-2-YL)-5-[4-(2- METHYL-1H-IMIDAZOL-1-YL)PHENYL]-6,7-DIHYDROPYRAZOLO[4, 3-E][1,4]DIAZEPIN-8(1H)-ONE | 4jib | B | Y655 I822 M847 I866 | EH9 | (2S,3R)-EHNA | 4c1i | B | Y655 I866 | 788 | N-BENZYL-4-METHYL-1-PHENYL[1,2,4]TRIAZOLO[4, 3-A]QUINOXALINE-8-CARBOXAMIDE | 4d09 | C | Y655 L774 M847 I866 | IBM | 3-ISOBUTYL-1-METHYL-9H-XANTHINE | 3itu | A | Y655 M847 | 1L6 | 1-(2-HYDROXYETHYL)-3-(2-METHYLBUTAN-2-YL)-5-[4-(2- METHYL-1H-IMIDAZOL-1-YL)PHENYL]-6,7-DIHYDROPYRAZOLO[4, 3-E][1,4]DIAZEPIN-8(1H)-ONE | 4jib | A | Y655 M847 | 1L6 | 1-(2-HYDROXYETHYL)-3-(2-METHYLBUTAN-2-YL)-5-[4-(2- METHYL-1H-IMIDAZOL-1-YL)PHENYL]-6,7-DIHYDROPYRAZOLO[4, 3-E][1,4]DIAZEPIN-8(1H)-ONE | 4jib | C | Y655 M847 | 1L6 | 1-(2-HYDROXYETHYL)-3-(2-METHYLBUTAN-2-YL)-5-[4-(2- METHYL-1H-IMIDAZOL-1-YL)PHENYL]-6,7-DIHYDROPYRAZOLO[4, 3-E][1,4]DIAZEPIN-8(1H)-ONE | 4jib | D | Y655 M847 | 19F | BAY60-7550 | 2-(3,4-DIMETHOXYBENZYL)-7-[(2R,3R)-2-HYDROXY-6- PHENYLHEXAN-3-YL]-5-METHYLIMIDAZO[5,1-F][1,2, 4]TRIAZIN-4(3H)-ONE | 4htx | A | Y655 M847 I866 | 19F | BAY60-7550 | 2-(3,4-DIMETHOXYBENZYL)-7-[(2R,3R)-2-HYDROXY-6- PHENYLHEXAN-3-YL]-5-METHYLIMIDAZO[5,1-F][1,2, 4]TRIAZIN-4(3H)-ONE | 4htx | B | Y655 M847 I866 | 19F | BAY60-7550 | 2-(3,4-DIMETHOXYBENZYL)-7-[(2R,3R)-2-HYDROXY-6- PHENYLHEXAN-3-YL]-5-METHYLIMIDAZO[5,1-F][1,2, 4]TRIAZIN-4(3H)-ONE | 4htx | C | Y655 M847 I866 | 19F | BAY60-7550 | 2-(3,4-DIMETHOXYBENZYL)-7-[(2R,3R)-2-HYDROXY-6- PHENYLHEXAN-3-YL]-5-METHYLIMIDAZO[5,1-F][1,2, 4]TRIAZIN-4(3H)-ONE | 4htx | D | Y655 M847 I866 |
Top |
Conservation information for LBS of PDE2A |
![]() |
LBS | AA sequence | # species | Species | D697 | SCMCHDLDHRG | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | D808 | LMTSCDLSDQT | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | D811 | SCDLSDQTKGW | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | E727 | EGSVMERHHFA | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | F830 | LIYKEFFSQGD | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | F862 | ELQISFMEHIA | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | H656 | RDPPYHNWMHA | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | H660 | YHNWMHAFSVS | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | H696 | ISCMCHDLDHR | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | H700 | CHDLDHRGTNN | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | H730 | VMERHHFAQAI | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | H773 | TDLAHHLRIFK | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | I822 | KTTRKIAELIY | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | I826 | KIAELIYKEFF | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | I866 | SFMEHIAMPIY | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | I870 | HIAMPIYKLLQ | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | L770 | ILATDLAHHLR | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | L774 | DLAHHLRIFKD | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | L809 | MTSCDLSDQTK | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | L858 | AYIPELQISFM | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | M845 | MGNRPMEMMDR | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | M847 | NRPMEMMDREK | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | M848 | RPMEMMDREKA | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | N704 | DHRGTNNSFQV | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | Q812 | CDLSDQTKGWK | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | Q859 | YIPELQISFME | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | S721 | AALYSSEGSVM | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | S861 | PELQISFMEHI | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | T768 | DIILATDLAHH | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | T805 | LCLLMTSCDLS | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | Y655 | YRDPPYHNWMH | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | Y827 | IAELIYKEFFS | 3 | Homo sapiens, Rattus norvegicus, Bos taurus |
![]() |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |